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Summary The main aim of epilepsy treatment is rapid and complete control of
seizures without antiepileptic drug (AED) side effects. This outcome is achieved in
60—70% of newly diagnosed patients. In refractory epilepsy, new AEDs render some
additional patients seizure free but make treatment more complex. The choice of
AEDs, their differing pharmacokinetics, efﬁcacy, tolerability and potential interac-
tions are multiplied. Up to of 75% of patients develop AED side effects, most AEDs can
cause paradoxical reactions, and when AED doses are changed seizures may worsen.
Despite the increased complexity of epilepsy treatment and the biomedical and psy-
chosocial consequences of uncontrolled seizures, many patients have difﬁculty ac-
cessing specialist services. A service that involves the epilepsy nurse specialist (ENS)
giving patients and General Practitioners (GPs) free access to treatment advice has re-
cently been established to improve care. Over a 2-week period 60 treatment-related
telephone or outpatient consultations were provided out of a total of 124 contacts.
Changes to the AED regimen were implemented in 44/60, and the GP was notiﬁed by
letter in 31/44. The audit results are presented and epilepsy treatment including AED
efﬁcacy, tolerability, interactions and side effects are discussed.
© 2003 BEA Trading Ltd. Published by Elsevier Ltd. All rights reserved.
Introduction
Epilepsy is a heterogenous condition with a range of
aetiologies, seizure types, severity and prognoses.
Uncontrolled seizures may devastate the patients’
conﬁdence, independence or career and are associ-
ated with increased morbidity and mortality. Stan-
dard AEDs are effective in about 70% of patients1
while newly available AEDs further improve seizure
free outcomes and by providing greater scope to
tailor treatment to the individual may reduce drug
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side effects2. Improving seizure control and mini-
mizing AED side effects are key factors in improv-
ing the quality of life among people with epilepsy3.
However, by virtue of a greater choice, new AEDs
also complicate treatment decisions, and increase
the number of likely drug combinations, potential
drug interactions and AED side effects. AEDs may
be seizure speciﬁc, may precipitate or exacerbate
other conditions, render co-medication less effec-
tive, and should be used with caution in different
patient groups. Complications may be prevented or
minimised with specialist management but special-
ists in epilepsy remain scarce. Despite the recent
expansion of knowledge in epilepsy and it’s subse-
quent development into a subspecialty of neurol-
ogy there has been little corresponding increase in
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epilepsy content or the duration of clinical train-
ing in neurology. The importance of improving ser-
vices was highlighted again by the National Sen-
tinel Clinical Audit of Epilepsy-related Death, which
revealed longstanding inadequate care for people
with epilepsy. Recommendations include improving
provider knowledge about epilepsy and the man-
agement of epilepsy, improving communication be-
tween hospital Consultants, A&E Departments and
the Primary Care Team, improving patient access to
epilepsy specialists, and providing better support
and education for patients4. The expansion of ENS
services is recommended as a way to improve ac-
cess and quality of care for people with epilepsy5.
Aed treatment
AED treatment has improved signiﬁcantly from the
1890s when Gowers classiﬁed epilepsy drugs into
two groups: those of ‘deﬁnite’ and ‘doubtful’ ben-
eﬁt. Drug efﬁcacy was largely opinion based and
most of the ‘deﬁnites’ and ‘doubtfuls’ were sub-
sequently found to be ineffective. The ‘standard’
AEDs which include Phenobarbital (PB), Mysoline
(MYS), Phenytoin (PHT), Primidone (PMD), Etho-
suximide (ESM), Carbamazepine (CBZ), Sodium Val-
proate (VPA), Clobazam (CLB), Clonazepam (CLP)
and Diazepam (DZP) became available between
1912 and the 1970s. While many of the standard
AEDs are effective and well tolerated, some have
difﬁcult pharmacokinetics. PHT, CBZ and VPA,
which are extensively metabolised by the liver, in-
duce or inhibit hepatic cytochrome P450 enzymes.
The metabolism rate of the AED or co-medication
may be altered by a drug which induces or inhibits
liver enzymes and this will affect its efﬁcacy or
tolerability. PHT and VPA are both highly protein
bound and easily displaced by other highly protein
bound drugs while PHT, which has non-linear ki-
netics, can rapidly cause toxicity following a small
dose increase6.
In the late 20th century, the ‘new’ AEDs, Vi-
gabatrin (VGB), Lamotrigine (LTG), Topiramate
(TPM), Gabapentin (GBP), Oxcarbazepine (OXC),
Tiagabine (TGB) and Levetiracetam (LEV) became
available. Most have improved pharmacokinetics
including linear kinetics, little or no protein bind-
ing or liver metabolism and longer half-lives7.
There are exceptions including LTG, which is exten-
sively metabolised by the liver. Concomitant VPA
dosing inhibits it’s metabolism which may double
the Lamotrigine elimination half-life, whereas its
half-life is reduced when co-administered with en-
zyme inducers such as CBZ or PHT. TPM, which also
undergoes some liver metabolism, inhibits a P450
enzyme involved in the metabolism of PHT. When
Topiramate is added to PHT, plasma concentrations
of PHT are increased by up to 25%, whereas concen-
trations of TPM are reduced by up to 50% when PHT
or CBZ are added8. Dose adjustments are required
to compensate for these interactions. Tiagabine is
highly protein bound and may be displaced by other
highly protein bound drugs and as GBP has a short
half-life, it requires three times daily dosing. Ox-
carbazepine was developed to provide a chemical
compound similar to CBZ but with fewer adverse
effects and improved pharmacokinetics. It has re-
duced enzyme induction and no auto induction but
like other enzyme inducing AEDs, does reduce the
efﬁcacy of the oral contraceptive pill9.
Special groups
As well as their improved pharmacokinetics new
AEDs are generally better tolerated, however, like
standard AEDs a high starting dose and rapid intro-
duction often precipitate or worsen side effects.
LTG commonly causes an allergic reaction that
may develop into Stevens Johnson reaction10. Nau-
sea, fatigue, headache, dizziness, diplopia, ataxia,
slowed cognition and mood changes are typical AED
side effects that may occur during the early intro-
duction stage or after a dose increase11. All AEDs
carry speciﬁc risks to patients of different gender,
ages and with concomitant pathology. Children are
more at risk of VPA-related hepatic disease, or PHT
induced coarsening of facial features, gum hyper-
trophy and hirsutism12. Barbiturate and benzodi-
azepines commonly cause drooling, sedation and
disturbances in behaviour, mood and cognition13.
VPA is associatedwith obesity, and in women poly-
cystic ovaries, menstrual irregularities, hyperan-
drogenism and hyperinsulinaemia although further
evidence is pending14. Hepatic enzyme inducing
AEDs interfere with the efﬁcacy of hormonal con-
traception, and increase the risk of bone metabolic
disorders such as osteomalacia and osteopenia15.
They may cause Vitamin K deﬁciency, predisposing
the newborn to haemorrhagic disease16. Many of
the standard AEDs have anti-folate effects and are
teratogenic. Malformations in neonates exposed to
AEDs in early development include orofacial clefts,
abdominal atresia, cardiac and skeletal malforma-
tions. Neural tube defects have been linked to PHT,
CBZ and VPA17,18. While the effects of new AEDs
on fetal development, bone health, fertility and
the menstrual cycle are not known, LEV, GBP and
LTG, and low doses of TPM do not interfere with
hormonal contraception. They show little tereto-
genic effect in animal studies and the early LTG
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pregnancy register outcomes, show no increased
risk over CBZ. LTG may be the AED of choice in el-
derly patients due to its long half-life which allows
once or twice daily dosing, its reduced interactions
with co-medications, alleged positive effect on
cognition and mood and good side effect proﬁle19.
However, most AEDs cause side effects, which in
the elderly can contribute to falls and fractures or
mimic dementia and lead to a premature loss of
independence20,21. VGB may cause a permanent
visual ﬁeld deﬁcit and is now rarely prescribed22.
Aed efﬁcacy
Most AEDs are more or less efﬁcacious in particu-
lar syndromes although the broad spectrum AEDs
LEV, TPM and VPA are effective in focal and gener-
alised epilepsy. TPM may completely control infan-
tile spasms23 and LTG, VPA and TPM are effective
in Lennox-Gasteau syndrome and learning disabled
patients with refractory epilepsy24—26. Reportedly
successful AED combinations include VPA and ESM
for refractory absences, CBZ or PHT for refractory
GTCSs, and VPA and LTG for refractory generalised
epilepsy.
AEDs that can worsen seizures include CBZ, which
may worsen typical and atypical absences, my-
oclonic and atonic seizures27, PB, whichmayworsen
absences and trigger absence status and PHT, which
may worsen myoclonic and absence seizures28,29.
Lamotrigine may exacerbate myoclonic seizures
in PME30,31 and both Gabapentin and Tiagabine
can precipitate episodes of non-convulsive status
epilepticus and myoclonic seizures32.
Audit and methodology
The epilepsy team at this tertiary referral centre
care for over 7000 patients, most with refractory
epilepsy, from throughout the United Kingdom.
Any patient or their GP has unrestricted access to
the ENS by telephone for information and treat-
ment advice. A standard statement ‘‘If there are
any medication problems contact the ENS . . . who
may advise on medication changes’’ is included in
the Consultant’s letter to the GP. Patients are also
referred to the ENS outpatient clinic for informa-
tion or support and supervision of planned drug
changes. The ENS implements AED changes out-
lined in the treatment plan but can initiate alter-
ations to the regimen. In such instances, the Con-
sultant is informed of the changes and may make
further recommendations. Over a 2-week period,
60 treatment-related consultations were provided
out of a total 124 contacts. A treatment-related
consultation is deﬁned as any consultation where
treatment issues, including AEDs, their side ef-
fects or seizure control are the main topics dis-
cussed. Fifty-ﬁve were conducted by telephone,
and ﬁve were face-to-face in the outpatient clinic.
Fifty-eight were with the patient, a carer or a
family member and two involved advice to the GP.
17/60 were ‘new patients’ to the ENS, 36/60 had
between 2 and 10 previous ENS contacts, 7/60 had
more than 10 previous contacts. One patient had
17 telephone contacts over the previous 2 years.
The time interval between the previous Consultant
outpatient appointment and contact with the ENS
was between 1 and 58 weeks. 46/60 patients had
been seen by the Consultant within the previous 16
weeks.
Results
The number of AEDs taken by patients were: nil
AEDs 1, 1 AED 9, 2 AEDs 24, 3 AEDs 21, 4 AEDs 5.
The AEDs and number of patients taking each are
as follows: CBZ 28, LEV 26, LTG 19, VPA 13, CLB
16, OXC 11, TPM 8, PB 7, PHT 6, GBP 1, DZP 2,
VGB 1, MYS 1. New and standard AEDs were com-
bined. The commonest combination, LEV and CBZ
was taken by 15 patients, either together or com-
bined with one or two other AEDs. Of the 25 pa-
tients taking 3 or more AEDs, all had different AED
combinations.
At the time of contact, 43/60 patients were un-
dertaking changes to the AED regimen. They were:
an AED introduction or dose increase 27, an AED
withdrawal or dose reduction 10, a simultaneous
AED introduction and withdrawal 5, simultaneous
increase of 2 AEDs 1.
The telephone contact was due to: AED side ef-
fects 17, ongoing seizures 12, recurrence or exac-
erbation of seizures 11, an improvement in seizures
4, a seizure-related injury 2, AED overdose 1, new
seizure presentation 1, prolonged post-ictal aggres-
sion 1.
Of the 17/60 with no recent AED change con-
tact was due to: ongoing or worsening seizures 8,
AED side effects 6, anxiety about or clariﬁcation of
AED regimen 3, advice about AED interaction with
co-medication 2, post-surgical complication 1.
The AED side effects reported were: headache 9,
ataxia 8, cognition problems 8, anxiety 6, low mood
6, visual disturbance 3, fatigue 3, dizziness 2, nau-
sea 2, insomnia 2, eye pain 2, aggression 2, depres-
sion 1, irritable mood 1, dysphasia 1, weakness 1,
tremor 1, ﬂu symptoms 1.
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Treatment response
44/60 patients were given advice about AED treat-
ment. The medication advice included: increase or
continue AED dose increases over time 19, reduce
AED dose or withdraw AED 16, initiate a new AED
7, maintain AED dose unchanged 5, slow the rate of
AED introduction 1, alter dose timing 1, withhold
AED dose 1, stop AED and re-challenge following the
resolution of symptoms 2, reinstate withdrawn AED
2, repeat AED serum level and review 2, record all
seizures in seizure diary 3, add AED prn for seizure
cluster or exacerbation 3.
Treatment issues discussed include: clariﬁ-
cation of the medication plan 1, post-surgical
wound infection 1, post-surgical word-ﬁnding dif-
ﬁculties 1, seizure-related hospital admission 2,
seizure-related injury 2, compliance 1, manage-
ment of peri-menstrual seizures 1, resolution of
AED side effects 3, improvement in seizures 3, anx-
iety management 4, treatment options 2, surgery
2, employment 3, prognosis 1, safety precautions
and injury prevention 2, independence issues 1.
Where the advice deviated from the Consultant’s
previous recommendations, AEDs and doses, recent
AED changes, seizure history, trigger factors, the
problem and recommendations were documented
in a letter to the GP that was copied to the pa-
tient and ﬁled in themedical records. Thirty-one GP
letters were generated from the 60 consultations.
Three patients were referred to the counselor, two
to the Consultant, two to the ENS outpatient clinic
and one to the GP.
Discussion
The majority of patients with refractory epilepsy
have complex treatment needs that are often
poorly addressed. Most patients attending this
hospital had frequent seizures, and often experi-
enced medication side effects and seizure-related
injuries. Sixty percent contacted the ENS for ur-
gent medical advice33. Patients referred to the
ENS generally take multiple AEDs, which include
combinations of both standard and new AEDs, and
undertake frequent AED dose or drug changes but
three times as many patients introducing rather
withdrawing an AED contacted the ENS with medi-
cation problems.
Ongoing seizures and seizure worsening which
occurred both in relation to and in the absence
of recent AED changes were the most frequent
causes for contact. The advice to the patient was
inﬂuenced by multiple factors including the AED
regimen, past seizure history and AED efﬁcacy,
recent AED changes, compliance, exacerbating
factors, concomitant medications, past episodes of
status epilepticus and other medical conditions. In-
structions to adjust the AED regimen were usually
accompanied by instructions to telephone the ENS
again within a speciﬁed time frame if there was no
improvement.
AED side effects were the next most frequent
reason for contact. Of 23 patients with AED side
effects, 16 had mood changes. The treatment ad-
vice took into account the severity and duration of
side effects, the AED doses, previous dose changes,
AED serum levels and dose timing, and adherence to
recommended therapy. As symptoms of other med-
ications or medical conditions may mimic AED side
effects, information about co-morbidity, treatment
with other medications and psychosocial problems
also inﬂuenced the treatment response. A common
interaction between LEV and CBZ was noted. LEV,
when added to maximum tolerated doses of CBZ re-
sulted in CBZ side effects, which resolved when the
CBZ dose was lowered. A policy of lowering the CBZ
dose when LEV is added to a maximum tolerated
CBZ dose has subsequently been adopted.
Patients with refractory epilepsy frequently have
underlying memory and cognition problems or de-
pression and anxiety, which in addition to ongoing
seizure activity, AEDs side effects and psychosocial
problems may affect comprehension and compli-
ance with medication. ENS telephone consultations
provide an opportunity to access not only new in-
formation but reinforce or clarify instructions about
AED doses and treatment changes to improve com-
pliance, and intervene to prevent or manage exist-
ing problems.
Summary
New knowledge about epilepsy and the availability
of new AEDs has made epilepsy treatment more
effective but also more complex. The number of
AEDs and possible combinations has expanded,
as have potential interactions between AEDs and
other medications. AED side effects and seizure
exacerbation are common treatment problems al-
though treatment-related queries are wide ranging
and specialist in nature. As the patient’s response
to treatment changes, which may be undertaken
over a period of weeks or months, can rarely be
predicted treatment advice and information may
be required within days or months of an outpa-
tient appointment. One way of improving services
and the care of people with epilepsy is by giving
patients’ unrestricted telephone and clinic access
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to a specialist. This has many advantages for pa-
tients including improving the continuity of care
and gaining immediate access to treatment ad-
vice that is tailored and speciﬁc to the individual.
Regular follow-up by a specialist optimises care
and minimises morbidity and mortality. Telephone
access to the ENS who has the authority and expe-
rience to advise patients on medication changes is
a cost effective way of providing this service and
meets many of the recommendations for improving
care made by the National Sentinel Clinical Audit
of Epilepsy-related Death. To provide a safe and
effective service the ENS should have advanced
training in epilepsy, access to the patient’s medical
history and clinical support from a specialist con-
sultant in epilepsy. When planning similar services
it should be noted that the advanced nursing skills
and training required for this post are in keeping
with those of a consultant nurse in epilepsy.
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